顺铂或卡铂加足叶乙甙治疗晚期肺癌105例临床分析

我所自1992年1月至1995年8月，用顺铂或卡钻加足叶乙甙治疗晚期肺癌105例，其中小细胞肺癌49例，非小细胞肺癌56例。顺铂组有效率小细胞肺癌为72．0％，非小细胞肺癌为38．5％；卡钥组有效率小细胞肺癌为79．2％，非小细胞肺癌为26．7％。两方案的主要毒性为胃肠道毒性和骨髓抑制，胃肠道毒性顺钥组较卡铂组为重，而骨髓抑制以卡铂组为明显。本文结果提示顺铂或卡铂加足叶乙甙治疗小细胞肺癌的有效率高，可作为治疗小细胞肺癌的首选方案。治疗非小细胞肺癌的有效率顺铂组稍高于卡铂组，但两组疗效均欠理想，为寻找治疗非小细胞肺癌更为有效的化疗方案，仍有待临床进一步探讨。

Etoposide Combined with Cisplatin or Carboplatin in the Treatment of 105 Cases of Advanced Lung Cancer

From January 1992 to Augus 1995, 105 patients with advanced lung cancer were treated with etopo-side combined with cisplatin (DDP) or carboplatin (CBP) in our institute. Forty-nine of them were ofsmall cell lung cancer (SCLC) and 56 of nonsmall cell lung cancer (NSCLC) .The response rate in DDPgroup was 72.0% in SCLC and 38.5% in NSCLC.In CBP group the response rate was 79.2% in SCLCand 26. 7% in NSCLC. The main side effects were gastrointestinal toxicity and myelosuppression. Gas-trointestinal toxicity was more severe in DDP po than in CBP mp and myelosuppression was morecommon in CBP group than in DDP group.This result suggested that in the treatmetn of SCLC,the regi-men of etoposide combined with PDD or CBP achieved a high response the and could serve as a first-se-lected treatmetn; in the treatmetn of NSCLC the response rate in PDD group was slightly higher than inCBP group, although both response rate were low. It is considered that further clinic research be conduct-ed so as to bo a more effective chemotherapy in the treatmetn of NSCLC.